Skip to main content
SpringerLink
Log in

Immune Responses in Acute and Chronic Hepatitis C

Implications for Prognosis and Therapy

  • Chapter
Liver Immunology

  • 1806 Accesses

Abstract

The hepatitis C story involves molecular biologists, virologists, immunologists, mathematicians, epidemiologists, and clinicians. It is one of the most impressive examples in modern medicine in which a combination of expertise from very different fields helped to identify the cause of a major disease and led to the development of effective therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359–362.

    PubMed  CAS  Google Scholar 

  2. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20–29.

    Google Scholar 

  3. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45: 607–616.

    PubMed  Google Scholar 

  4. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005; 40(Suppl 5): S330–S335.

    PubMed  Google Scholar 

  5. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36 (5 Suppl 1):S93–S98.

    PubMed  Google Scholar 

  6. Wiegand J, Potthoff A, Manns MP, Wedemeyer H.Acute hepatitis C infection: can immunology teach us the right way to treat? Curr Hepatitis Rep 2004; 3:148–156.

    Google Scholar 

  7. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395–1406.

    PubMed  CAS  Google Scholar 

  8. Meyer MF, Wedemeyer H, Monazahian M, Dreesman J, Manns MP, Lehmann M. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiol Infect 2006; 1–7.

    Google Scholar 

  9. Cooksley WG, Butterworth LA. Hepatitis C virus infection in health care workers referred to a hepatitis clinic. Med J Aust 1996; 164: 656–658.

    PubMed  CAS  Google Scholar 

  10. Ammon A, Reichart PA, Pauli G, Petersen LR. Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures. Epidemiol Infect 2000; 125: 407–413.

    PubMed  CAS  Google Scholar 

  11. Proietti L, Malaponte G, Libra M,et al. Analysis of hepatitis C virus infection among health-care workers: an observational study. Minerva Gastroenterol Dietol 2005; 51:255–259.

    PubMed  CAS  Google Scholar 

  12. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003; 31(Suppl 2):22–27.

    PubMed  Google Scholar 

  13. Gerlach JT, Diepolder HM, Zachoval R,et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80–88.

    PubMed  Google Scholar 

  14. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455–463.

    PubMed  CAS  Google Scholar 

  15. Seeff LB, Miller RN, Rabkin CS,et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105–111.

    PubMed  CAS  Google Scholar 

  16. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32:91–96.

    PubMed  CAS  Google Scholar 

  17. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 2005; 43:590–598.

    PubMed  Google Scholar 

  18. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228–1233.

    PubMed  CAS  Google Scholar 

  19. Vogt M, Lang T, Frosner G,et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866–870.

    PubMed  CAS  Google Scholar 

  20. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97–104.

    PubMed  Google Scholar 

  21. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25:3834–3847.

    PubMed  CAS  Google Scholar 

  22. Kamal SM, Bianchi L, Al Tawil A, et al. Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. J Infect Dis 2001; 184:972–982.

    PubMed  CAS  Google Scholar 

  23. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4:437–444.

    PubMed  Google Scholar 

  24. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024–1029.

    PubMed  Google Scholar 

  25. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436:933–938.

    PubMed  CAS  Google Scholar 

  26. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106–115.

    PubMed  CAS  Google Scholar 

  27. Rumi MG, De Filippi F, La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402–406.

    PubMed  CAS  Google Scholar 

  28. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350–1359.

    PubMed  CAS  Google Scholar 

  29. Rice CM. Is CD81 the key to hepatitis C virus entry? Hepatology 1999; 29:990–992.

    PubMed  CAS  Google Scholar 

  30. Crotta S, Stilla A, Wack A, D’Andrea A, Nuti S, D’Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:35–41.

    PubMed  CAS  Google Scholar 

  31. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195:43–49.

    PubMed  CAS  Google Scholar 

  32. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74:10,055–10,062.

    PubMed  CAS  Google Scholar 

  33. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 2006; 87: 1075–1084.

    PubMed  CAS  Google Scholar 

  34. Wakita T, Pietschmann T, Kato T,et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791–796.

    PubMed  CAS  Google Scholar 

  35. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623–626.

    PubMed  CAS  Google Scholar 

  36. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34:417–423.

    PubMed  CAS  Google Scholar 

  37. Griffin SD, Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003; 535:34–38.

    PubMed  CAS  Google Scholar 

  38. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145–1148.

    PubMed  CAS  Google Scholar 

  39. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77–81.

    PubMed  CAS  Google Scholar 

  40. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferoninducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107–110.

    PubMed  CAS  Google Scholar 

  41. Hinrichsen H, Benhamou Y, Wedemeyer H,et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347–1355.

    PubMed  CAS  Google Scholar 

  42. Zeuzem S, Sarrazin C, Rouzier R,et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha). Hepatology 2005; 42:233A–234A.

    Google Scholar 

  43. Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 2005; 42:234A–235A.

    Google Scholar 

  44. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438–1447.

    PubMed  CAS  Google Scholar 

  45. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 2001; 82: 723–733.

    PubMed  CAS  Google Scholar 

  46. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99:15,669–15,674.

    PubMed  CAS  Google Scholar 

  47. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75:7059–7066.

    PubMed  CAS  Google Scholar 

  48. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109:451–457.

    PubMed  CAS  Google Scholar 

  49. Herzer K, Falk CS, Encke J,et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003; 77:8299–8309.

    PubMed  CAS  Google Scholar 

  50. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872–874.

    PubMed  CAS  Google Scholar 

  51. Tseng CT, Miskovsky E, Houghton M, Klimpel GR. Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 2001; 33:1312–1320.

    PubMed  CAS  Google Scholar 

  52. Zibert A, Kraas W, Ross RS, et al. Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol 1999; 30:177–184.

    PubMed  CAS  Google Scholar 

  53. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339–344.

    PubMed  CAS  Google Scholar 

  54. Thomson M, Nascimbeni M, Havert MB, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003; 77: 862–870.

    PubMed  CAS  Google Scholar 

  55. Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189:1846–1855.

    PubMed  Google Scholar 

  56. Petska JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutrallizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Nat Acd Sci USA 2007;104:6025–6030.

    Google Scholar 

  57. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a singlesource outbreak of hepatitis C. Nat Med 2000; 6: 578–582.

    PubMed  CAS  Google Scholar 

  58. Wiegand J, Jackel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40:98–107.

    PubMed  CAS  Google Scholar 

  59. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245–252.

    PubMed  CAS  Google Scholar 

  60. Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. J Gen Virol 1998; 79:705–714.

    PubMed  CAS  Google Scholar 

  61. Goutagny N, Fatmi A, De L, et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003; 187:1951–1958.

    PubMed  Google Scholar 

  62. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120:512–524.

    PubMed  CAS  Google Scholar 

  63. Kanto T, Hayashi N, Takehara T,et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162:5584–5591.

    PubMed  CAS  Google Scholar 

  64. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004; 103:1026–1029.

    PubMed  CAS  Google Scholar 

  65. Ulsenheimer A, Gerlach JT, Jung MC, et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 2005; 41:643–651.

    PubMed  Google Scholar 

  66. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215–229.

    PubMed  CAS  Google Scholar 

  67. Chang KM, Thimme R, Melpolder JJ, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33:267–276.

    PubMed  CAS  Google Scholar 

  68. Lechner F, Wong DK, Dunbar PR,et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499–1512.

    PubMed  CAS  Google Scholar 

  69. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550–5558.

    PubMed  CAS  Google Scholar 

  70. He XS, Rehermann B, Lopez-Labrador FX,et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999; 96:5692–5697.

    PubMed  CAS  Google Scholar 

  71. Grabowska AM, Lechner F, Klenerman P, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31:2388–2394.

    PubMed  CAS  Google Scholar 

  72. Accapezzato D, Francavilla V, Rawson P, et al. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. Eur J Immunol 2004; 34:438–446.

    PubMed  CAS  Google Scholar 

  73. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000; 106:1239–1249.

    PubMed  CAS  Google Scholar 

  74. Grakoui A, John WE, Hanson HL, Walker C, Ahmed R. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol 2006; 45:468–472.

    PubMed  CAS  Google Scholar 

  75. Urbani S, Amadei B, Fisicaro P, et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006; 44:126–139.

    PubMed  CAS  Google Scholar 

  76. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55:362–369.

    PubMed  CAS  Google Scholar 

  77. Neumann-Haefelin C, McKiernan S, Ward S, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006; 43:563–572.

    PubMed  CAS  Google Scholar 

  78. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38: 1468–1476.

    PubMed  CAS  Google Scholar 

  79. Manigold T, Shin EC, Mizukoshi E, et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006; 107:4424–4432.

    PubMed  CAS  Google Scholar 

  80. Rushbrook SM, Ward SM, Unitt E, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005; 79:7852–7859.

    PubMed  CAS  Google Scholar 

  81. Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virusspecific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79:7860–7867.

    PubMed  CAS  Google Scholar 

  82. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113:963–972.

    PubMed  CAS  Google Scholar 

  83. Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200: 1593–1604.

    PubMed  CAS  Google Scholar 

  84. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15:883–895.

    PubMed  CAS  Google Scholar 

  85. Cox AL, Mosbruger T, Mao Q, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201: 1741–1752.

    PubMed  CAS  Google Scholar 

  86. Chang KM, Rehermann B, McHutchison JG, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997; 100: 2376–2385.

    PubMed  CAS  Google Scholar 

  87. Seifert U, Liermann H, Racanelli V, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004; 114: 250–259.

    PubMed  CAS  Google Scholar 

  88. Soderholm J, Ahlen G, Kaul A, et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 2006; 55:266–274.

    PubMed  CAS  Google Scholar 

  89. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28:225–230.

    PubMed  CAS  Google Scholar 

  90. Nascimbeni M, Mizukoshi E, Bosmann M, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77: 4781–4793.

    PubMed  CAS  Google Scholar 

  91. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99:15,661–15,668.

    PubMed  CAS  Google Scholar 

  92. Nascimbeni M, Rehermann B. Chronic HCV infection and the clonality of intrahepatic T cells. J Hepatol 2003; 38:677–680.

    PubMed  Google Scholar 

  93. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virusspecific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346–355.

    PubMed  CAS  Google Scholar 

  94. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36:743–754.

    PubMed  CAS  Google Scholar 

  95. Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005; 79:12,979–12,988.

    PubMed  CAS  Google Scholar 

  96. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40:87–97.

    PubMed  CAS  Google Scholar 

  97. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859–866.

    PubMed  CAS  Google Scholar 

  98. Scognamiglio P, Accapezzato D, Casciaro MA,et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162:6681–6689.

    PubMed  CAS  Google Scholar 

  99. Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78:12,252–12,258.

    PubMed  CAS  Google Scholar 

  100. Mehta SH, Cox A, Hoover DR,et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478–1483.

    PubMed  Google Scholar 

  101. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961–966.

    PubMed  CAS  Google Scholar 

  102. Leroux-Roels G, Depla E, Hulstaert F,et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22:3080–3086.

    PubMed  CAS  Google Scholar 

  103. Firbas C, Jilma B, Tauber E,et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006; 24:4343–4353.

    PubMed  CAS  Google Scholar 

  104. Nevens F, Roskams T, Van Vlierberghe H,et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38:1289–1296.

    PubMed  CAS  Google Scholar 

  105. Wedemeyer H, Van Vlierberghe H, Blum H, et al. E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: results of a 15 months, placebo-controlled trial. J Hepatol 2006;44:5229.

    Google Scholar 

  106. Manns MP, Berg T, Wedemeyer H, et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 2004; 40:251 A.

    Google Scholar 

  107. Welsh RM, Selin LK. No one is naïve: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2:417–426.

    PubMed  CAS  Google Scholar 

  108. Selin LK, Brehm MA, Naumov YN, et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev 2006; 211:164–181.

    PubMed  CAS  Google Scholar 

  109. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med 2005; 201:523–533.

    PubMed  CAS  Google Scholar 

  110. Lauer GM, Ouchi K, Chung RT, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:6104–6113.

    PubMed  CAS  Google Scholar 

  111. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001; 75:11,392–11,400.

    PubMed  CAS  Google Scholar 

  112. Kennedy PT, Urbani S, Moses RA,et al. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006; 43:602–611.

    PubMed  CAS  Google Scholar 

  113. Cornberg M, Chen AT, Wilkinson LA, et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 2006; 116:1443–1456.

    PubMed  CAS  Google Scholar 

  114. Urbani S, Amadei B, Fisicaro P, et al. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 2005; 201:675–680.

    PubMed  CAS  Google Scholar 

  115. Wedemeyer H, Jackel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 2004; 39:1201–1203.

    PubMed  Google Scholar 

  116. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452–1457.

    PubMed  CAS  Google Scholar 

  117. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEPNET acute-HCV-II study. Hepatology 2006; 43:250–256.

    PubMed  CAS  Google Scholar 

  118. Wedemeyer H, Caselmann WH, Manns MP. Combination therapy of chronic hepatitis C: an important step but not the final goal! J Hepatol 1998; 29:1010–1014.

    PubMed  CAS  Google Scholar 

  119. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20:931–938.

    PubMed  CAS  Google Scholar 

  120. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:3487–3493.

    PubMed  CAS  Google Scholar 

  121. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922–924.

    PubMed  CAS  Google Scholar 

  122. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: phase IB results. Hepatology 2005; 42:276A–277A.

    Google Scholar 

  123. Wedemeyer H, Berg T, Manns MP,et al. Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. Hepatol 2005; 42:9–10.

    Google Scholar 

  124. Bacon BR, McHutchison JG, Gordon SC, et al. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon TM), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005; 128: A696.

    Google Scholar 

  125. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724–731.

    PubMed  CAS  Google Scholar 

  126. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118: 655–660.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany

    Heiner Wedemeyer MD

  2. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

    Michael P. Manns MD

Authors
  1. Heiner Wedemeyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Cornberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael P. Manns MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, CA

    M. Eric Gershwin MD, FACP

  2. Departments of Medicine and Surgery Baylor Liver Health, Baylor College of Medicine, Houston, TX

    John M. Vierling MD, FACP

  3. Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Hannover, Germany

    Michael P. Manns MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Wedemeyer, H., Cornberg, M., Manns, M.P. (2007). Immune Responses in Acute and Chronic Hepatitis C. In: Gershwin, M.E., Vierling, J.M., Manns, M.P. (eds) Liver Immunology. Humana Press. https://doi.org/10.1007/978-1-59745-518-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-518-3_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-818-8

  • Online ISBN: 978-1-59745-518-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation